Ocular Therapeutix (OCUL) Gross Profit (2014 - 2026)

Ocular Therapeutix has reported Gross Profit for 13 years, with the latest figure at $11.5 million in Q2 2026.

• Gross Profit for Q2 2026 came in at $11.5 million, changed 0.44% year-over-year; the trailing twelve-month figure through Jun 2026 was $45.3 million (down 10.5% YoY), and the FY2025 annual result was $45.4 million, down 21.89% from the prior year.
• Gross Profit climbed to $11.5 million in Q2 2026, from $9.5 million in the prior quarter.
• Over five years, Gross Profit peaked at $15.9 million in Q4 2024 and troughed at $9.4 million in Q1 2025.
• A 5-year average of $12.5 million and a median of $12.5 million in 2023 frame the typical range for Gross Profit.
• The widest annual swing landed in 2022, when Gross Profit soared 84.29%; it then slipped 29.83% in 2025.
• A 5-year view of Gross Profit shows it stood at $13.1 million in 2022, then climbed by 2.69% to $13.4 million in 2023, then rose by 18.17% to $15.9 million in 2024, then declined by 26.47% to $11.7 million in 2025, then slipped by 1.65% to $11.5 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $11.5 million in Q2 2026, $9.5 million in Q1 2026, and $11.7 million in Q4 2025.